Abstract

Endothelin-1 (ET-1) is a 21 amino acid peptide with diverse biological activity that has been implicated in numerous diseases. ET-1 is a potent mitogen regulator of smooth muscle tone, and inflammatory mediator that may play a key role in diseases of the airways, pulmonary circulation, and inflammatory lung diseases, both acute and chronic. This review will focus on the biology of ET-1 and its role in lung disease.

Highlights

  • ET-1, ET-2, and ET-3 are members of a peptide family that has been the subject of much interest in the past decade

  • endothelin A (ETA) receptors in normal lung are found in greatest abundance on vascular and airway smooth muscle, whereas endothelin B (ETB) receptors are most often found on the endothelium

  • Chronically hypoxic lungs with increased ETB receptor expression, augmented vasodilation is due to increased ETB mediated nitric oxide (NO) release that is inhibited by hypoxic ventilation, while inhibition of NO synthesis leads to increased ET-1 mediated vasoconstriction [85,90,91,92]

Read more

Summary

Introduction

ET-1, ET-2, and ET-3 are members of a peptide family that has been the subject of much interest in the past decade. Our laboratory and that of Highsmith identified this peptide vasoconstrictor secreted from endothelial cells [1,2,3] that was subsequently isolated, sequenced, cloned, and named by Yanagisawa in 1988 [4]. The many diverse and overlapping functions of these peptides have since implicated endothelins in both homeostatic mechanisms as well as diseases of the lungs. This review will focus on the role of endothelins ( ET-1), emphasizing the need to better understand endothelin biology and function in a wide variety of disorders including diseases of the airways and pulmonary vasculature, lung tumors, the acute respiratory distress syndrome, and fibrotic diseases (Table 1)

Endothelin biochemistry
Vasculature Endothelial cells Platelets Smooth muscle
Airway diseases
Pulmonary vascular disease
Lung transplantation and rejection
Pulmonary malignancies
Acute respiratory distress syndrome
Pulmonary fibrosis
Findings
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.